Hospital-Treated Gram-Negative Infections | Disease Landscape & Forecast | G7 | 2023
The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited GNI armamentarium. Despite the launch of novel antibiotics, such as AbbVie / Pfizer’s Avycaz / Zavicefta, Merck & Co.’s Zerbaxa and Recarbrio, and Shionogi’s Fetroja / Fetcroja, unmet need remains for additional treatment options with novel mechanisms of action and with efficacy in patients with drug-resistant infections, which are associated with high rates of mortality. Although the market is heavily genericized and cost-containment measures have limited the commercial success of emerging therapies, innovative push-and-pull market approaches such as value-based pricing (VBP) and de-linked drug reimbursement models promise to encourage and support future antibiotics development.
QUESTIONS ANSWERED
- How large are the treatable HABP / VABP / HCAP, CSSSI / SSI, cIAI, BSI, and UTI populations? What are the resistance rates to different classes of antibiotics across several pathogen species?
- What is the state of treatment for hospital-treated GNIs? What are the most important drugs and why? What clinical needs remain unfulfilled?
- What impact will the emerging antibiotic therapies have on the GNI therapy market? Which emerging therapies generate the most enthusiasm among thought leaders? How will ID specialists in different markets make treatment decisions among the emerging therapies in the future?
- On what attributes will pipeline therapies need to improve to compete with currently marketed products?
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Primary research: 29 country-specific interviews with thought-leading infectious disease specialists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed cases of GNIs by country, segmented by key infections (HABP / VABP / HCAP, CSSSI / SSI, cIAI, BSI, and UTI), pathogens (E. Coli, Pseudomonas, Acinetobacter, Klebsiella), and resistance types.
Forecast: 10-year, annualized, drug-level sales and patient share of key GNI therapies through 2032, segmented by brands / generics, geography, and five key infection types
Emerging therapies: Phase 3/PR: 5+ drugs; Phase 2: 15+ drugs; coverage of select early-phase products
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
